Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buserelin + human chorionic gonadotropin
- Development stage
- Unknown
- Lead developer
- Hoechst
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous
01
Overview
A combination therapy used in assisted reproduction and fertility treatments. Buserelin is a synthetic GnRH agonist that initially stimulates and then suppresses gonadotropin release, while human chorionic gonadotropin (hCG) mimics LH action to trigger final oocyte maturation and ovulation. This combination is used in IVF protocols where buserelin prevents premature LH surge and hCG induces ovulation at the optimal time.
02
Targets
LHCGR (Luteinizing hormone/choriogonadotropin receptor)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on buserelin + human chorionic gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buserelin + human chorionic gonadotropin.